Tempest Therapeutics Inc. has announced its entry into a securities purchase agreement with a single institutional investor, as detailed in a recent prospectus filed with the Securities and Exchange Commission. The agreement allows Tempest to issue and sell 405,000 shares of common stock and prefunded warrants for 334,000 additional shares in a registered direct offering. The offering, priced at $6.25 per share of common stock and $6.249 per prefunded warrant, is aimed at raising funds to support strategic alternatives and general corporate purposes. The net proceeds, combined with existing cash reserves, are expected to fund the company's operations into the second quarter of 2026, although this estimate may change based on future financial needs. The company has engaged Cooley LLP to provide a legal opinion on the validity of the securities being issued.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。